Coronavirus (COVID-19): Important Information From Scripps Learn more
Investigational Drug for Aspirin Exacerbated Respiratory Disease (AERD)
In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.
Andrew A. White, M.D.
This study will compare the investigational drug ifetroban to a placebo for improving symptoms and quality of life in patients with AERD. Participants will receive study drug or placebo once daily for up to 8 weeks, and will have a telephone visit at week 1 with additional clinic follow-up visits at 4, 8, and 10 weeks.
Have a history of physician-diagnosed asthma
Have a history of at least two reactions to oral aspirin
Be at least 18 years of age or older
Active AERD symptoms within two weeks of starting treatment
Be a current smoker or have used tobacco within the last three months
Have participated in a clinical trial with ifetroban within the past three months.
Participants will also be asked to donate nasal fluid, blood and urine specimens to be stored and used for future research on AERD.